Midostaurin: a magic bullet that blocks mast cell expansion and activation
Open accessThe DOI matches its Crossref record; 78 of the 79 references it cites were found in a registry or an index.
Abstract
Clinically relevant features in patients with systemic mastocytosis (SM) include the cosmetic burden of lesional skin, mediator-related symptoms, and organ damage resulting from mast cell (MC) infiltration in advanced forms of SM. Regardless of the SM variant, expansion of neoplastic MC in the skin and other organs is triggered by mutant forms of KIT, the most prevalent being D816V. Activation of MC with subsequent release of chemical mediators is often caused by IgE-dependent mechanisms in these patients. Midostaurin, also known as PKC412, blocks the kinase activity of wild-type KIT and KIT D816V, counteracts KIT-dependent growth of neoplastic MC, and inhibits IgE-dependent mediator secretion. Based on this activity-profile, the drug has been used for treatment of patients with advanced SM. Indeed, encouraging results have been obtained with the drug in a recent multi-center phase II trial in patients with advanced SM, with an overall response rate of 60% and a substantial decrease in the burden of neoplastic MC in various organs. Moreover, midostaurin improved the overall survival and relapse-free survival in patients with advanced SM compared with historical controls. In addition, midostaurin was found to improve mediator-related symptoms and quality of life, suggesting that the drug may also be useful in patients with indolent SM suffering from mediator-related symptoms resistant to conventional therapies or those with MC activation syndromes. Ongoing and future studies will determine the actual value of midostaurin-induced MC depletion and MC deactivation in these additional indications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“For instance, midostaurin is a broadly acting signal transduction inhibitor that recognizes kinase targets (such as SYK) downstream of the IgE receptor.”
From Selecting the Right Criteria and Proper Classification to Diagnose Mast Cell Activation Syndromes: A Critical Review (2021) · cites this paper as [94]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A quantitative analysis of kinase inhibitor selectivity
Karaman, M. W., Herrgard, S., Treiber, D. K., Gallant, P., Atteridge, C. E., Campbell, B. T., Chan, K. W., Ciceri, P., Davis, M. I., Edeen, P. T., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1358 · Cited by 2,466 · cited 2×
“Molecular targets were identified in a cell-free screen [42] and in a chemical proteomics approach using primary neoplastic mast cells [43].”
BackgroundStaurosporine, a potent inhibitor of phospholipidCa++dependent protein kinase
Tamaoki, T., Nomoto, H., Takahashi, I., Kato, Y., Morimoto, M., & Tomita, F. (1986) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(86)90008-2 · Cited by 2,452 · cited 1×
“Midostaurin, originally termed PKC412, is a semi-synthetic derivative of the alkaloid staurosporine, a well-known inhibitor of PKC (Figure 1A) [41].”
BackgroundBorst, O., Walker, B., Münzer, P., Russo, A., Schmid, E., Faggio, C., Bigalke, B., Laufer, S., Gawaz, M., & Lang, F. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350110 · Cited by 1,860
Diagnostic criteria and classification of mastocytosis: a consensus proposal
Valent, P., Horny, H.-P., Escribano, L., Longley, B. J., Li, C. Y., Schwartz, L. B., Marone, G., Nuñez, R., Akin, C., Sotlar, K., et al. (2001) · Leukemia Research · doi:10.1016/s0145-2126(01)00038-8 · Cited by 1,108
Self-citationNagata, H., Worobec, A. S., Oh, C. K., Chowdhury, B. A., Tannenbaum, S., Suzuki, Y., & Metcalfe, D. D. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.23.10560 · Cited by 872
Furitsu, T., Tsujimura, T., Tono, T., Ikeda, H., Kitayama, H., Koshimizu, U., Sugahara, H., Butterfield, J. H., Ashman, L. K., & Kanayama, Y. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116761 · Cited by 816
Valent, P., Akin, C., Escribano, L., Födinger, M., Hartmann, K., Brockow, K., Castells, M., Sperr, W. R., Kluin‐Nelemans, H. C., Hamdy, N. A. T., et al. (2007) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2007.01807.x · Cited by 750 · cited 1×
“For those who are not eligible for SCT or refuse this therapy, investigational drugs are usually recommended [5, 9, 10, 22, 23].”
BackgroundSelf-citationLongley, B. J., Tyrrell, L., Lu, S.-Z., Ma, Y.-S., Langley, K., Ding, T.-G., Duffy, T., Jacobs, P., Tang, L. H., & Modlin, I. (1996) · Nature Genetics · doi:10.1038/ng0396-312 · Cited by 607
Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors
Lim, K.-H., Tefferi, A., Lasho, T. L., Finke, C., Patnaik, M., Butterfield, J. H., McClure, R. F., Li, C.-Y., & Pardanani, A. (2009) · Blood · doi:10.1182/blood-2009-02-205237 · Cited by 588
Brockow, K., Jofer, C., Behrendt, H., & Ring, J. (2008) · Allergy · doi:10.1111/j.1398-9995.2007.01569.x · Cited by 523
Mast Cells, Mastocytosis, and Related Disorders
Theoharides, T. C., Valent, P., & Akin, C. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1409760 · Cited by 518
Self-citationEfficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis
Gotlib, J., Kluin-Nelemans, H. C., George, T. I., Akin, C., Sotlar, K., Hermine, O., Awan, F. T., Hexner, E., Mauro, M. J., Sternberg, D. W., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1513098 · Cited by 488 · cited 12×
“low-grade nausea, vomiting, and diarrhea (Table 3) [39].”
BackgroundMethodSelf-citationClassification and Diagnosis of Mastocytosis: Current Status
Metcalfe, D. D. (1991) · Journal of Investigative Dermatology · doi:10.1111/1523-1747.ep12468882 · Cited by 346
PKC412--a protein kinase inhibitor with a broad therapeutic potential.
Fabbro, D., Ruetz, S., Bodis, S. B., Pruschy, M. N., Csermak, K., Man, A., Campochiaro, P. A., Wood, J. M., O'Reilly, T., & Meyer, T. (2000) · PubMed · Cited by 302
Arock, M., Sotlar, K., Akin, C., Broesby-Olsen, S., Hoermann, G., Escribano, L., Kristensen, T. K., Kluin-Nelemans, H. C., Hermine, O., Dubreuil, P., et al. (2015) · Leukemia · doi:10.1038/leu.2015.24 · Cited by 290
Self-citationShah, N. P., Lee, F. Y., Luo, R., Jiang, Y., Donker, M., & Akin, C. (2006) · Blood · doi:10.1182/blood-2005-10-3969 · Cited by 273
Self-citationHeidel, F., Solem, F. K., Breitenbuecher, F., Lipka, D. B., Kasper, S., Thiede, M. H., Brandts, C., Serve, H., Roesel, J., Giles, F., et al. (2006) · Blood · doi:10.1182/blood-2005-06-2469 · Cited by 270
Comprehensive mutational profiling in advanced systemic mastocytosis
Schwaab, J., Schnittger, S., Sotlar, K., Walz, C., Fabarius, A., Pfirrmann, M., Kohlmann, A., Grossmann, V., Meggendorfer, M., Horny, H.-P., et al. (2013) · Blood · doi:10.1182/blood-2013-04-496448 · Cited by 263
Self-citationMast cells and mast cell neoplasia: a review*
LENNERT, K., & PARWARESCH, M. R. (1979) · Histopathology · doi:10.1111/j.1365-2559.1979.tb03017.x · Cited by 263
Gleixner, K. V., Mayerhofer, M., Aichberger, K. J., Derdak, S., Sonneck, K., Böhm, A., Gruze, A., Samorapoompichit, P., Manley, P. W., Fabbro, D., et al. (2006) · Blood · doi:10.1182/blood-2005-07-3022 · Cited by 250 · cited 8×
“Furthermore, midostaurin was found to induce apoptosis and growth arrest in primary neoplastic MC obtained from patients with advanced SM (Figure 1C) [25, 27].”
BackgroundSelf-citationGrowney, J. D., Clark, J. J., Adelsperger, J., Stone, R., Fabbro, D., Griffin, J. D., & Gilliland, D. G. (2005) · Blood · doi:10.1182/blood-2004-12-4617 · Cited by 249 · cited 2×
“In subsequent studies, midostaurin was found to suppress not only the kinase activity of wild-type (wt) KIT, but also mutated forms of the receptor, including D816V [25, 27, 35, 36].”
BackgroundCladribine therapy for systemic mastocytosis
Kluin-Nelemans, H. C. (2003) · Blood · doi:10.1182/blood-2003-05-1699 · Cited by 248
Self-citationGotlib, J. (2005) · Blood · doi:10.1182/blood-2005-04-1568 · Cited by 243 · cited 18×
“1 expressing the KIT V560G mutation (but not KIT D816V) and HMC-1.”
BackgroundResultSelf-citationValent, P. (2003) · Leukemia Research · doi:10.1016/s0145-2126(02)00168-6 · Cited by 234 · cited 1×
“For those who are not eligible for SCT or refuse this therapy, investigational drugs are usually recommended [5, 9, 10, 22, 23].”
BackgroundSelf-citationPhase I and Pharmacokinetic Study of PKC412, an Inhibitor of Protein Kinase C
Propper, D. J., McDonald, A. C., Man, A., Thavasu, P., Balkwill, F., Braybrooke, J. P., Caponigro, F., Graf, P., Dutreix, C., Blackie, R., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.5.1485 · Cited by 233
Horny, H.-P., & Valent, P. (2001) · Leukemia Research · doi:10.1016/s0145-2126(01)00021-2 · Cited by 227
Self-citationEffects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit
Akin, C., Brockow, K., D'Ambrosio, C., Kirshenbaum, A. S., Ma, Y., Longley, B. J., & Metcalfe, D. D. (2003) · Experimental Hematology · doi:10.1016/s0301-472x(03)00112-7 · Cited by 224
Self-citationCools, J., Stover, E. H., Boulton, C. L., Gotlib, J., Legare, R. D., Amaral, S. M., Curley, D. P., Duclos, N., Rowan, R., Kutok, J. L., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00108-9 · Cited by 216
Self-citationDiagnosis and treatment of systemic mastocytosis: state of the art
Valent, P., Akin, C., Sperr, W. R., Horny, H., Arock, M., Lechner, K., Bennett, J. M., & Metcalfe, D. D. (2003) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04575.x · Cited by 211 · cited 1×
“For those who are not eligible for SCT or refuse this therapy, investigational drugs are usually recommended [5, 9, 10, 22, 23].”
BackgroundSelf-citationAkin, C., & Metcalfe, D. D. (2004) · Annual Review of Medicine · doi:10.1146/annurev.med.55.091902.103822 · Cited by 209
Self-citationSignal Transduction by the High-Affinity Immunoglobulin E Receptor FcεRI: Coupling Form to Function
Nadler, M. J. S., Matthews, S. A., Turner, H., & Kinet, J.-P. (2001) · Advances in Immunology · doi:10.1016/s0065-2776(01)76022-1 · Cited by 203 · cited 1×
“SYK is an IgEreceptor downstream target that plays a major role in IgE-dependent MC activation [47, 48].”
BackgroundMastocytosis: current concepts in diagnosis and treatment
L., E., C., A., M., C., A., O., & D., M. (2002) · Annals of Hematology · doi:10.1007/s00277-002-0575-z · Cited by 201
Self-citationLevis, M., Brown, P., Smith, B. D., Stine, A., Pham, R., Stone, R., DeAngelo, D., Galinsky, I., Giles, F., Estey, E., et al. (2006) · Blood · doi:10.1182/blood-2006-04-015743 · Cited by 199
Lim, K. H., Pardanani, A., Butterfield, J. H., Li, C., & Tefferi, A. (2009) · American Journal of Hematology · doi:10.1002/ajh.21561 · Cited by 194
A Case of Intestinal Mastocytosis Misdiagnosed as Crohn's Disease
Reggiani, S., Cosso, L., Adriani, A., Pantaleoni, S., Risso, A., Vittone, F., Chiusa, L., Sapone, N., & Astegiano, M. (2015) · Case Reports in Gastroenterology · doi:10.1159/000430946 · Cited by 193
Hematopoietic Stem-Cell Transplantation for Advanced Systemic Mastocytosis
Ustun, C., Reiter, A., Scott, B. L., Nakamura, R., Damaj, G., Kreil, S., Shanley, R., Hogan, W. J., Perales, M.-A., Shore, T., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.2018 · Cited by 190 · cited 9×
“Indeed, it has been shown that SCT is a potentially curative approach in advanced SM, particularly in patients with SM-AHN [21, 73].”
BackgroundSelf-citationPardanani, A., Lim, K.-H., Lasho, T. L., Finke, C., McClure, R. F., Li, C.-Y., & Tefferi, A. (2009) · Blood · doi:10.1182/blood-2009-05-220145 · Cited by 187
Valent, P., Sperr, W. R., Schwartz, L. B., & Horny, H.-P. (2004) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2004.02.045 · Cited by 161
Self-citationMast Cell Leukemia: Report of a Case and Review of the Literature
TRAVIS, W. D., LI, C.-Y., HOAGLAND, H. C., TRAVIS, L. B., & BANKS, P. M. (1986) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(12)62636-6 · Cited by 160
Stone, R. M., Mandrekar, S., Sanford, B. L., Geyer, S., Bloomfield, C. D., Dohner, K., Thiede, C., Marcucci, G., Lo-Coco, F., Klisovic, R. B., et al. (2015) · Blood · doi:10.1182/blood.v126.23.6.6 · Cited by 159
Arock, M., & Valent, P. (2010) · Expert Review of Hematology · doi:10.1586/ehm.10.42 · Cited by 158
Self-citationLong-term efficacy and safety of cladribine (2-CdA) in adult patients with mastocytosis
Barete, S., Lortholary, O., Damaj, G., Hirsch, I., Chandesris, M. O., Elie, C., Hamidou, M., Durieu, I., Suarez, F., Grosbois, B., et al. (2015) · Blood · doi:10.1182/blood-2014-12-614743 · Cited by 153
Self-citationFritsche‐Polanz, R., Jordan, J., Feix, A., Sperr, W. R., Sunder‐Plassmann, G., Valent, P., & Födinger, M. (2001) · British Journal of Haematology · doi:10.1046/j.1365-2141.2001.02783.x · Cited by 143
Self-citationProtein tyrosine kinase Syk in mast cell signaling
Siraganian, R. P., Zhang, J., Suzuki, K., & Sada, K. (2002) · Molecular Immunology · doi:10.1016/s0161-5890(02)00068-8 · Cited by 143 · cited 1×
“SYK is an IgEreceptor downstream target that plays a major role in IgE-dependent MC activation [47, 48].”
BackgroundFéger, F., Ribadeau Dumas, A., Leriche, L., Valent, P., & Arock, M. (2002) · International Archives of Allergy and Immunology · doi:10.1159/000048179 · Cited by 132
Self-citationLierman, E., Michaux, L., Beullens, E., Pierre, P. G., Marynen, P., Cools, J., & Vandenberghe, P. (2009) · Leukemia · doi:10.1038/leu.2009.2 · Cited by 131 · cited 1×
“Secondary mutations have been described in AML patients with FLT3 ITD mutations [65] and patients with PDGFR mutations [66], but not in patients with advanced SM.”
BackgroundHow I treat patients with advanced systemic mastocytosis
Valent, P., Sperr, W. R., & Akin, C. (2010) · Blood · doi:10.1182/blood-2010-08-292144 · Cited by 130 · cited 1×
“For those who are not eligible for SCT or refuse this therapy, investigational drugs are usually recommended [5, 9, 10, 22, 23].”
BackgroundSelf-citationFodinger, M., Fritsch, G., Winkler, K., Emminger, W., Mitterbauer, G., Gadner, H., Valent, P., & Mannhalter, C. (1994) · Blood · doi:10.1182/blood.v84.9.2954.2954 · Cited by 117 · cited 1×
“However, due to the long-maturation time of MCcommitted stem- and progenitor cells and the long survival of mature MC in the tissues [64], it may take about 2 years until a strong KIT-inhibitor is able to induce complete MC deficiency [63].”
BackgroundSelf-citationTraina, F., Visconte, V., Jankowska, A. M., Makishima, H., O’Keefe, C. L., Elson, P., Han, Y., Hsieh, F. H., Sekeres, M. A., Mali, R. S., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0043090 · Cited by 116
Saleh, R., Wedeh, G., Herrmann, H., Bibi, S., Cerny-Reiterer, S., Sadovnik, I., Blatt, K., Hadzijusufovic, E., Jeanningros, S., Blanc, C., et al. (2014) · Blood · doi:10.1182/blood-2013-10-534685 · Cited by 109 · cited 1×
“Similar effects were also seen when applying the drug in the recently established human MC lines ROSA WT and ROSA D816V [53].”
BackgroundSelf-citationvon Bubnoff, N. C. C., Engh, R. A., Åberg, E., Sänger, J., Peschel, C., & Duyster, J. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2923 · Cited by 104
Tyrosine kinase inhibitors in the treatment of systemic mastocytosis
Ustun, C., DeRemer, D. L., & Akin, C. (2011) · Leukemia Research · doi:10.1016/j.leukres.2011.05.006 · Cited by 102 · cited 1×
“In subsequent studies, midostaurin was found to suppress not only the kinase activity of wild-type (wt) KIT, but also mutated forms of the receptor, including D816V [25, 27, 35, 36].”
BackgroundSelf-citationConsensus Opinion on Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis
Ustun, C., Gotlib, J., Popat, U., Artz, A., Litzow, M., Reiter, A., Nakamura, R., Kluin-Nelemans, H. C., Verstovsek, S., Gajewski, J., et al. (2016) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2016.04.018 · Cited by 100 · cited 2×
“In other SM-AHN patients, additional driver-lesions may be found, such as JAK2 V617F or the AML-associated t(8;21) RUNX1-RUNX1T1 fusion-gene.”
BackgroundSelf-citationWeisberg, E., Wright, R. D., Jiang, J., Ray, A., Moreno, D., Manley, P. W., Fabbro, D., Hall–Meyers, E., Catley, L., Podar, K., et al. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.09.017 · Cited by 95
Self-citationClonal analysis of NRAS activating mutations in KIT-D816V systemic mastocytosis
Wilson, T. M., Maric, I., Simakova, O., Bai, Y., Ching Chan, E., Olivares, N., Carter, M., Maric, D., Robyn, J., & Metcalfe, D. D. (2011) · Haematologica · doi:10.3324/haematol.2010.031690 · Cited by 93
Gleixner, K. V., Mayerhofer, M., Sonneck, K., Gruze, A., Samorapoompichit, P., Baumgartner, C., Lee, F. Y., Aichberger, K. J., Manley, P. W., Fabbro, D., et al. (2007) · Haematologica · doi:10.3324/haematol.11339 · Cited by 93
Self-citationKrauth, M. ‐., Mirkina, I., Herrmann, H., Baumgartner, C., Kneidinger, M., & Valent, P. (2009) · Clinical & Experimental Allergy · doi:10.1111/j.1365-2222.2009.03353.x · Cited by 89 · cited 3×
“Furthermore, midostaurin was found to block IgE-dependent mediator release in human MC and basophils [38].”
BackgroundSelf-citationInvestigation into CYP3A4-mediated drug–drug interactions on midostaurin in healthy volunteers
Dutreix, C., Munarini, F., Lorenzo, S., Roesel, J., & Wang, Y. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2287-6 · Cited by 89
Kneidinger, M., Schmidt, U., Rix, U., Gleixner, K. V., Vales, A., Baumgartner, C., Lupinek, C., Weghofer, M., Bennett, K. L., Herrmann, H., et al. (2008) · Blood · doi:10.1182/blood-2007-08-104372 · Cited by 84 · cited 1×
“The effects of midostaurin on histamine release are dose-dependent, without a rebound effect or paradoxical stimulating effect at low concentrations, described for dasatinib in its effects on IgE-mediated histamine release [59].”
BackgroundSelf-citationGleixner, K. V., Mayerhofer, M., Cerny-Reiterer, S., Hörmann, G., Rix, U., Bennett, K. L., Hadzijusufovic, E., Meyer, R. A., Pickl, W. F., Gotlib, J., et al. (2011) · Blood · doi:10.1182/blood-2010-06-289959 · Cited by 73 · cited 2×
“For example, the synergistic effect of the drug combination ‘midostaurinþ dasatinib’ was explained by inhibitory effects of dasatinib on BTK and LYN, since cooperative drug effects (midostaurinþ dasatinib) were also obtained when applying the drug plus small interfering RNA (siRNA), namely ‘midostaurinþBTK-siRNA’ or ‘…”
BackgroundSelf-citationThe Liver, Spleen, and Lymph Nodes in Mastocytosis
Metcalfe, D. D. (1991) · Journal of Investigative Dermatology · doi:10.1111/1523-1747.ep12469022 · Cited by 69
Midostaurin in Advanced Systemic Mastocytosis
Chandesris, M.-O., Damaj, G., Canioni, D., Brouzes, C., Lhermitte, L., Hanssens, K., Frenzel, L., Cherquaoui, Z., Durieu, I., Durupt, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmc1515403 · Cited by 67 · cited 3×
“Results from first clinical trials are now available and indeed suggest that a majority of patients with advanced SM respond to therapy with this agent [39, 40].”
BackgroundSelf-citationAichberger, K. J., Gleixner, K. V., Mirkina, I., Cerny-Reiterer, S., Peter, B., Ferenc, V., Kneidinger, M., Baumgartner, C., Mayerhofer, M., Gruze, A., et al. (2009) · Blood · doi:10.1182/blood-2008-08-175190 · Cited by 65
Self-citationCerny‐Reiterer, S., Rabenhorst, A., Stefanzl, G., Herndlhofer, S., Hoermann, G., Müllauer, L., Baumgartner, S., Beham‐Schmid, C., Sperr, W. R., Mannhalter, C., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.3074 · Cited by 64 · cited 3×
“However, due to the long-maturation time of MCcommitted stem- and progenitor cells and the long survival of mature MC in the tissues [64], it may take about 2 years until a strong KIT-inhibitor is able to induce complete MC deficiency [63].”
BackgroundSelf-citationPeter, B., Winter, G. E., Blatt, K., Bennett, K. L., Stefanzl, G., Rix, U., Eisenwort, G., Hadzijusufovic, E., Gridling, M., Dutreix, C., et al. (2016) · Leukemia · doi:10.1038/leu.2015.242 · Cited by 63 · cited 17×
“(PDGFRA), PDGFRB, vascular endothelial growth factor receptor KDR, and FES (Table 1) [37, 42, 43].”
BackgroundResultSelf-citationGotlib, J., DeAngelo, D. J., George, T. I., Corless, C. L., Linder, A., Langford, C., Dutreix, C., Gross, S., Nikolova, Z., & Graubert, T. (2010) · Blood · doi:10.1182/blood.v116.21.316.316 · Cited by 52 · cited 3×
“The first study, an investigatorinitiated trial of 26 patients with advanced SM, documented an organ response rate of 69%, including 50% major responses [62].”
BackgroundSelf-citationValent, P., Ghannadan, M., Akin, C., Krauth, M. ‐., Selzer, E., Mayerhofer, M., Sperr, W. R., Arock, M., Samorapoompichit, P., Horny, H. ‐., et al. (2004) · European Journal of Clinical Investigation · doi:10.1111/j.0960-135x.2004.01369.x · Cited by 51
Self-citationGleixner, K. V., Peter, B., Blatt, K., Suppan, V., Reiter, A., Radia, D. H., Hadzijusufovic, E., & Valent, P. (2013) · Haematologica · doi:10.3324/haematol.2012.079202 · Cited by 51
Self-citationKIT Mutations in Mastocytosis and Their Potential as Therapeutic Targets
Gotlib, J. R. (2006) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2006.05.003 · Cited by 49
Self-citationDose‐ and Time‐Dependent Pharmacokinetics of Midostaurin in Patients With Diabetes Mellitus
Wang, Y., Yin, O. Q. P., Gräf, P., Kisicki, J. C., & SCHRAN, H. F. (2008) · The Journal of Clinical Pharmacology · doi:10.1177/0091270008318006 · Cited by 48
CD52 is a molecular target in advanced systemic mastocytosis
Hoermann, G., Blatt, K., Greiner, G., Putz, E. M., Berger, A., Herrmann, H., Cerny‐Reiterer, S., Gleixner, K. V., Walz, C., Höetzenecker, K., et al. (2014) · The FASEB Journal · doi:10.1096/fj.14-250894 · Cited by 44 · cited 3×
“Hoermann G, Blatt K, Greiner G et al. CD52 is a molecular target in advanced systemic mastocytosis.”
BackgroundSelf-citationKrauth, M., Böhm, A., Agis, H., Sonneck, K., Samorapoompichit, P., Florian, S., Sotlar, K., & Valent, P. (2006) · Experimental Hematology · doi:10.1016/j.exphem.2006.09.008 · Cited by 43 · cited 3×
“Hoermann G, Blatt K, Greiner G et al. CD52 is a molecular target in advanced systemic mastocytosis.”
BackgroundSelf-citationPeter, B., Cerny‐Reiterer, S., Hadzijusufovic, E., Schuch, K., Stefanzl, G., Eisenwort, G., Gleixner, K. V., Hoermann, G., Mayerhofer, M., Kundi, M., et al. (2013) · Journal of Leukocyte Biology · doi:10.1189/jlb.1112609 · Cited by 40
Self-citationHow we diagnose and treat WHO-defined systemic mastocytosis in adults
Tefferi, A., Verstovšek, S., & Pardanani, A. D. (2007) · Haematologica · doi:10.3324/haematol.12324 · Cited by 26 · cited 1×
“For those who are not eligible for SCT or refuse this therapy, investigational drugs are usually recommended [5, 9, 10, 22, 23].”
BackgroundWedeh, G., Cerny‐Reiterer, S., Eisenwort, G., Herrmann, H., Blatt, K., Hadzijusufovic, E., Sadovnik, I., Müllauer, L., Schwaab, J., Hoffmann, T., et al. (2015) · Leukemia · doi:10.1038/leu.2015.138 · Cited by 25
Self-citationExpression of programmed cell death ligand-1 in mastocytosis correlates with disease severity
Rabenhorst, A., Leja, S., Schwaab, J., Gehring, M., Förster, A., Arock, M., Reiter, A., Raap, U., & Hartmann, K. (2015) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2015.07.006 · Cited by 18 · cited 2×
“Instrinsic resistance of leukemic stem cells (LSC) has been postulated in various malignancies and linked to certain molecules, including multidrug-resistance genes, such as MDR-1, immune-checkpoint receptors, such as PD-L1 (PD1 ligand) or CD47 (‘don’t eat me’ receptor), and interactions between LSC and the so-called…”
BackgroundSelf-citationGotlib, J. R., Kluin‐Nelemans, H. C., George, T. I., Akin, C., Sotlar, K., Hermine, O., Awan, F. T., Hexner, E. O., Mauro, M. J., Morariu, R., et al. (2013) · Blood · doi:10.1182/blood.v122.21.106.106 · Cited by 11 · cited 5×
“Because of midostaurin’s capacity to block IgE-mediated activation of MC and its ability to improve mediator-related symptoms in SM patients [39, 60], an additional indication worthy of future investigation may be secondary (IgE-dependent) MCAS and IgE-dependent allergies unresponsive to classical antimediator therapy.”
BackgroundSelf-citationIdentification of a Neoplastic Stem Cell in Human Mast Cell Leukemia
Eisenwort, G., Peter, B., Blatt, K., Cerny‐Reiterer, S., Hoermann, G., Sadovnik, I., Bilban, M., Rülicke, T., Willmann, M., Schwaab, J., et al. (2014) · Blood · doi:10.1182/blood.v124.21.817.817 · Cited by 7 · cited 5×
“Hoermann G, Blatt K, Greiner G et al. CD52 is a molecular target in advanced systemic mastocytosis.”
BackgroundSelf-citation
Research works printed but not linked: 1
- Van Anrooij B Oude Elberink JNG Span LF Midostaurin (PKC412) in indolent systemic mastocytosis: a phase 2 trial EHA Learning Center 2016 Abstract P303
Cited by
Zhong, Q., Xiao, X., Qiu, Y., Xu, Z., Chen, C., Chong, B., Zhao, X., Hai, S., Li, S., An, Z., et al. (2023) · MedComm · doi:10.1002/mco2.261 · Cited by 442
Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus Proposal
Valent, P., Akin, C., Hartmann, K., Alvarez-Twose, I., Brockow, K., Hermine, O., Niedoszytko, M., Schwaab, J., Lyons, J. J., Carter, M. C., et al. (2021) · HemaSphere · doi:10.1097/hs9.0000000000000646 · Cited by 317
Self-citationUnderstanding human mast cells: lesson from therapies for allergic and non-allergic diseases
Kolkhir, P., Elieh-Ali-Komi, D., Metz, M., Siebenhaar, F., & Maurer, M. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-021-00622-y · Cited by 193
Weiler, C. R., Austen, K. F., Akin, C., Barkoff, M. S., Bernstein, J. A., Bonadonna, P., Butterfield, J. H., Carter, M., Fox, C. C., Maitland, A., et al. (2019) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2019.08.023 · Cited by 123
Self-citationNew Insights into the Pathogenesis of Mastocytosis: Emerging Concepts in Diagnosis and Therapy
Valent, P., Akin, C., Sperr, W. R., Horny, H., Arock, M., Metcalfe, D. D., & Galli, S. J. (2022) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-031521-042618 · Cited by 108
Self-citation
Metadata
- Authors
- Valent, P., Akin, C., Hartmann, K., George, T. I., Sotlar, K., Peter, B., Gleixner, K. V., Blatt, K., Sperr, W. R., Manley, P. W., Hermine, O., Kluin-Nelemans, H. C., Arock, M., Horny, H.-P., Reiter, A., & Gotlib, J.
- Affiliations
- Ludwig Boltzmann Institute for Hematology and Oncology (AT)
- University of Michigan (US)
- University of Lübeck (DE)
- University of New Mexico (US)
- Paracelsus Medical University (AT)
- Novartis (Switzerland) (CH)
- Sorbonne Paris Cité (FR)
- Centre National de la Recherche Scientifique (FR)
- Pathologisches Institut (DE)
- Heidelberg University (DE)
- Stanford Cancer Institute (US)
- Corresponding author
- Valent, P.
- ORCID
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2017-10
- Volume
- 28
- Issue
- 10
- Pages
- 2367-2376
- ISSN
- 0923-7534 (ISSN-L)
- PMC
- PMC7115852
- OpenAlex
- W2753355630
- Cited by
- 79
- References
- 79
- Citations by year
- 2026: 4 · 2025: 4 · 2024: 4 · 2023: 13 · 2022: 8 · 2021: 14 · 2020: 11 · 2019: 15 · 2018: 5
- FWCI
- 0.87
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 793 d)
- Locations
- Annals of Oncology (publishedVersion)
- PubMed (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion, other-oa)
- PubMed Central (acceptedVersion)
- edoc (University of Basel) (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- Funders
- Austrian Science Fund (F4704-B20)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Mast cells and histamine
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal Tumor Research and Treatment
- Health Sciences › Medicine › Rheumatology › Eosinophilic Disorders and Syndromes
- Keywords
- midostaurin, systemic mastocytosis, KIT D816V mutation, mast cell activation, tyrosine kinase inhibitors, mast cell degranulation, mast cell activation syndrome, indolent systemic mastocytosis, survival outcomes
- MeSH terms
- Antineoplastic Agents, Humans, Mast Cells, Multicenter Studies as Topic, Clinical Trials, Phase II as Topic, Drug Resistance, Neoplasm, Staurosporine, Mastocytosis, Systemic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.